The development of the oral macrocyclic peptide enlicitide (MK-0616), for the treatment of hypercholesterolemia

Enlicitide/MK-0616 is a novel oral macrocyclic peptide which binds to PCSK9 with similar affinity as anti-PCSK9 monoclonal antibodies, at 1/100th the molecular size. This presentation will provide an overivew of the identification/optimization of enlicitide and the clinical development of this novel drug candidate, currently being progressed through Phase 3 clinical trials.